# NOL9

Source: https://onco.cc/targets/nol9/  
OnCo record `nol9` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NOL9 (Polynucleotide 5'-hydroxyl-kinase NOL9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.

## Summary

Polynucleotide kinase that can phosphorylate the 5'-hydroxyl groups of single-stranded and double-stranded RNA and DNA substrates. Involved in rRNA processing and its kinase activity is required for the processing of the 32S precursor into 5.8S and 28S rRNAs, more specifically for the generation of the major 5.8S(S) form. Required for the efficient pre-rRNA processing of internal transcribed spacer 2 (ITS2).

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: nucleolar protein 9; Polynucleotide 5'-hydroxyl-kinase NOL9; FLJ23323; NET6; Grc3
- Tags: cancer-genes-wave
- Symbol: NOL9
- Class: kinase
- Biology: Polynucleotide kinase that can phosphorylate the 5'-hydroxyl groups of single-stranded and double-stranded RNA and DNA substrates. Involved in rRNA processing and its kinase activity is required for the processing of the 32S precursor into 5.8S and 28S rRNAs, more specifically for the generation of the major 5.8S(S) form. Required for the efficient pre-rRNA processing of internal transcribed spacer 2 (ITS2). Associates with LAS1L to form an ITS2 pre-rRNA endonuclease-kinase complex and is responsible for the transport of this complex into the nucleolus. Location: Nucleus; Nucleus, nucleolus (UniProt). Locus 1p36.31 (HGNC).
- Where found: Diffuse large B-cell lymphoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:26265: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:26265
- UniProt Q5SY16: https://www.uniprot.org/uniprotkb/Q5SY16/entry
- NCBI Gene 79707: https://www.ncbi.nlm.nih.gov/gene/79707
- Ensembl ENSG00000162408: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162408

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)

---
JSON: https://onco.cc/api/v1/entities/nol9.json